Summary:
- This article discusses the results of a clinical trial that evaluated the use of Taltz (ixekizumab) and Zepbound (tirzepatide) together to treat patients with type 2 diabetes and psoriatic arthritis.
- The study found that the combination of these two medications was more effective in improving symptoms and reducing disease activity compared to using either medication alone.
- This research suggests that combining these two therapies may be a promising approach for treating patients with both type 2 diabetes and psoriatic arthritis, a condition that affects the joints and skin.